Dennis Jungherz
Leipzig, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.
Journal: HemaSphere
Published: October 27, 2025
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.
Journal: Cancer research
Published: February 27, 2025
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
Journal: Leukemia
Published: January 10, 2025
"Clone-specific" antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers.
Journal: Signal transduction and targeted therapy
Published: May 21, 2024
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.
Journal: Nature communications
Published: November 15, 2023
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
Journal: Blood
Published: October 12, 2023
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Journal: The Journal of clinical investigation
Published: January 04, 2023
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Journal: Nature communications
Published: March 21, 2022
Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations.
Journal: Frontiers in oncology
Published: September 13, 2021
Generation of phytase chimeras with low sequence identities and improved thermal stability.
Journal: Journal of biotechnology
Published: February 17, 2021
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Journal: Biomarker research
Published: September 05, 2020
Last Updated: 09/26/2026